The highlights of the World Conference on Lung Cancer 2021 now on medtoday
05.11.2021 13:36
At Lung Cancer today, a ten-member faculty consisting of German-speaking top lung oncologists will present the most important study results on a total of five thoracic oncological topic areas from the World Conference on Lung Cancer 2021, which took place in September 2021. The slide-supported contributions will be available free of charge for the entire next year and as a PDF download on www.medtoday.de.
Cologne, October 2021 - Due to the ongoing COVID-19 pandemic, the 22nd annual congress of the International Association for the Study of Lung Cancer (IASLC) took place purely virtually for the second time from September 8th to 14th, 2021. For the Lung Cancer today project, ten German lung oncology experts selected the most important studies from the submitted abstracts that could be important for treatment practice in Germany and presented the data in informative and slide-supported video contributions. In detailed educational contributions, our experts also gave an overview of the current supply situation in Germany and thus introduce the new WCLC data.
This year's faculty at Lung Cancer today
- Early lung cancer:
PD Dr. med. Wilfried Eberhardt, Essen University Hospital and Ruhrland Clinic
Dr. med. Nikolay Frost, Charité - University Medicine Berlin
- Immunotherapy for advanced lung cancer:
Univ.-Prof. Dr. med. Annals Bleckmann, University Hospital Münster
PD Dr. med. Niels Reinmuth, Asklepios Specialist Clinics Munich-Gauting
- Pathology and biomarkers:
PD Dr. med. Luke Heukamp, Institute for Hematopathology Hamburg
Prof. Dr. med. Katharina Tiemann, Institute for Hematopathology Hamburg
- SCLC, mesothelioma and more:
Dr. med. Cornelia Kropf-Sanchen, Ulm University Hospital
Univ.-Prof. Dr. med. Michael Thomas, Heidelberg University Hospital
- Roomtargeted therapy for advanced lung cancer
Prof. Dr. med. Frank Griesinger, Pius Hospital Oldenburg
Prof. Dr. med. Dr. rer. nat. Sonja Loges, Mannheim University Medical Center
In the 15-minute “In Focus” discussion rounds on the five thoracic oncology topics, the experts also controversially discussed various studies and discussed them lively with a view to the care situation in Germany. Of all the studies submitted to the 2021 WCLC, the following studies attracted the most interest from our experts and were then discussed in detail in the cross-topic final discussion:
- Immunotherapy for advanced lung cancer
Johnson ML et al., “Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study”
- Targeted therapy for advanced lung cancer
Spira A et al., “Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy.”
- Early lung cancer
Altorki N et al., “IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab”
- SCLC, mesothelioma and more
Paz-Ares L et al., “Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial.”
Chan JM et al., “Signatures of Plasticity and Immunosuppression in a Single-Cell Atlas of Human Small Cell Lung Cancer”
- Pathology and biomarkers
Lau S CM et al., “PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC”
All articles from Lung Cancer today will be published for the first time this year www.medtoday.de made available, an innovative scientific platform that bundles all of art tempi communications gmbh's reports on medical congresses on one website. The experts' video presentations are available for one year in German and as a PDF download. Access to the articles is possible after a one-time, free registration on medtoday.
The Lung Cancer today program is editorially independent and was made possible by gold sponsors AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Janssen Oncology and MSD Sharp & Dohme GmbH.